Department of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki, 852-8521, Japan.
J Gastroenterol. 2013 Oct;48(10):1160-70. doi: 10.1007/s00535-012-0730-9. Epub 2013 Jan 11.
Patients with primary biliary cirrhosis (PBC) exhibit a variety of clinical manifestations and patterns of disease progression. The aim of this study was to identify genetic determinants of PBC progression.
A total of 52 tag single nucleotide polymorphisms (SNPs) of 11 candidate genes involved in regulating bile acid synthesis were analyzed by polymerase chain reaction (PCR)-restriction fragment length polymorphism, -high resolution melting curve analysis, or -direct DNA sequencing in 315 Japanese patients with PBC.
In this study, four tag SNPs of CYP7A1 (rs1457043, rs8192870, rs3808607, and rs3824260), two tag SNPs of HNF4A (rs6017340 and 6031587), and one SNP of PPARGC1A (rs8192678) showed a significant association with PBC progression. In addition, a dual luciferase assay revealed that the polymorphism of rs3808607 in CYP7A1 altered the expression of CYP7A1 in HepG2. Specifically, the CYP7A1 promoter carrying the risk G allele for PBC progression induced higher expression of CYP7A1 under both the normal and cholestatic conditions in vitro as compared to another promoter carrying the non-risk T allele.
These results suggested that the genetic variants of CYP7A1 and its transcriptional activators (HNF4A and PPARGC1A) may activate bile acid synthesis, resulting in the accumulation of bile acids in hepatocytes and eventually leading to the predisposition to PBC progression. Thus, the regulation of CYP7A1 expression may represent an attractive therapeutic target for cholestatic liver diseases including PBC.
原发性胆汁性肝硬化(PBC)患者表现出多种临床表现和疾病进展模式。本研究旨在确定 PBC 进展的遗传决定因素。
对 315 例日本 PBC 患者的 11 个候选基因(涉及胆汁酸合成调节)的 52 个标签单核苷酸多态性(SNP)进行聚合酶链反应(PCR)-限制性片段长度多态性、-高分辨率熔解曲线分析或-DNA 直接测序分析。
在这项研究中,CYP7A1(rs1457043、rs8192870、rs3808607 和 rs3824260)的四个标签 SNP、HNF4A(rs6017340 和 6031587)的两个标签 SNP 和 PPARGC1A(rs8192678)的一个 SNP 与 PBC 进展显著相关。此外,双荧光素酶报告基因实验表明 CYP7A1 中 rs3808607 的多态性改变了 HepG2 中 CYP7A1 的表达。具体而言,与携带非风险 T 等位基因的另一个启动子相比,携带 PBC 进展风险 G 等位基因的 CYP7A1 启动子在体外正常和胆汁淤积条件下均可诱导 CYP7A1 更高的表达。
这些结果表明,CYP7A1 及其转录激活因子(HNF4A 和 PPARGC1A)的遗传变异可能激活胆汁酸合成,导致肝细胞内胆汁酸堆积,最终导致 PBC 进展的易感性。因此,CYP7A1 表达的调节可能成为包括 PBC 在内的胆汁淤积性肝病的一个有吸引力的治疗靶点。